Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-TIL051 in anti-PD1 resistant metastatic NSCLC
NCT05676749Phase 1Terminated
- Sponsor
- AbelZeta
- Start
- Feb 2024
- Primary completion
- Dec 2025
- Modality
- Prophylactic Vaccines, Tumor-Infiltrating Lymphocytes (TILs), Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous tumor-infiltrating lymphocytes C-TIL051 in non-small cell lung cancer (NSCLC), sponsored by AbelZeta. Primary endpoints: Adverse Events at 24 months and Dose Limiting Toxicities at 24 months. Started Feb 2024; status: terminated.
02
Drugs
autologous tumor-infiltrating lymphocytes C-TIL051
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05676749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05676749.